Abstract
Eleven dogs with cutaneous mast cell tumors (MCTs) were treated with surgery and iridium-192 ((192)Ir) interstitial brachytherapy. Minimum tumor doses ranged from 47.2 to 63.3 Gy. Treated tumors were classified as grade II (n=7) or III (n=4). Five dogs had recurrences with a median progression-free interval of 1391 days, and six dogs had no recurrence at a median follow-up time of 942 days. Acute adverse effects were well tolerated, and late effects were mild. One dog developed a second tumor of a different cell type in the radiation treatment field.
MeSH terms
-
Animals
-
Brachytherapy / methods
-
Brachytherapy / veterinary*
-
Dog Diseases / pathology
-
Dog Diseases / radiotherapy*
-
Dogs
-
Dose-Response Relationship, Radiation
-
Female
-
Iridium Radioisotopes / adverse effects
-
Iridium Radioisotopes / therapeutic use*
-
Male
-
Mast-Cell Sarcoma / pathology
-
Mast-Cell Sarcoma / radiotherapy
-
Mast-Cell Sarcoma / veterinary*
-
Neoplasm Recurrence, Local / veterinary
-
Neoplasm Staging / veterinary
-
Retrospective Studies
-
Skin Neoplasms / pathology
-
Skin Neoplasms / radiotherapy
-
Skin Neoplasms / veterinary*
-
Treatment Outcome